Ronald Martell, Jasper Therapeutics CEO
October 14, 2024 11:20 AM EDT
R&D

Jasper shares ral­ly as chron­ic hives drug scores in small, ear­ly tri­al

Ayisha Sharma

News Reporter

Jasper Ther­a­peu­tics’ an­ti-c-KIT an­ti­body has shown promise in a Phase 1b/2a test in peo­ple with cer­tain ir­ri­ta­ble skin con­di­tions, send­ing its shares ris­ing on Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

No­var­tis ends mid-stage IPF tri­al, will keep test­ing drug in PAH

Catal­ent sells New Jer­sey plant to Bel­gian CD­MO, plans mov­ing HQ else­where

Pfiz­er de­tails re­sults from failed Phase 3 tri­al of Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py 

FDA to re­con­sid­er re­moval of Lil­ly's GLP-1 drug from short­age list, a win for com­pound­ing phar­ma­cies

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times